Aptose Biosciences to be acquired by Hanmi Pharmaceutical for C$2.41 per share in cash

Aptose Biosciences Inc.

Hanmi subsidiary will acquire all outstanding Aptose shares at C$2.41 each, a 28% premium over the 30-day VWAP of C$1.88 on TSX.
Aptose board unanimously recommends the arrangement after unanimous recommendation from a special committee of independent directors.
Transaction requires approval by two-thirds of votes cast and minority approval excluding Hanmi affiliates; special meeting by Jan 16, 2026.
Non-solicitation provisions with a C$300,000 expense fee payable to Hanmi if agreement terminated under certain conditions.
Post-closing, Aptose shares will be delisted from TSX and the company will cease reporting under Canadian securities legislation.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.98

Aptose Biosciences Inc. entered into Arrangement Agreement with Hanmi Pharmaceuticals Co. Ltd. and HS North America Ltd. valued at C$2.41 in cash per Common Share (effective 2025-11-18).

Action: entry
Agreement: merger
Counterparty: Hanmi Pharmaceuticals Co. Ltd. and HS North America Ltd.
Value: C$2.41 in cash per Common Share
Effective: 2025-11-18

Exact text from the filing

On November 18, 2025, Aptose Biosciences Inc. (the “ Company ”), Hanmi Pharmaceuticals Co. Ltd. (“ Hanmi ”) and HS North America Ltd., a wholly owned subsidiary of Hanmi (“ Hanmi Purchaser ” and together with Hanmi, the “ Hanmi Purchasers ”), entered into a definitive arrangement agreement (the “ Arrangement Agreement ”) pursuant to which Hanmi Purchaser will acquire all of the issued and outstanding common shares of the Company

View on SEC.gov

Browse all material agreements →

Aptose Biosciences Inc. filing history →

Source: SEC EDGAR

accession 0001193125-25-294108

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.